Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $485,000 | +42.2% | 32,085 | +11.7% | 0.00% | – |
Q1 2022 | $341,000 | -29.3% | 28,735 | -3.4% | 0.00% | – |
Q4 2021 | $482,000 | -54.8% | 29,754 | -20.3% | 0.00% | -100.0% |
Q3 2021 | $1,066,000 | -15.4% | 37,354 | +0.2% | 0.00% | 0.0% |
Q2 2021 | $1,260,000 | +11.8% | 37,271 | +0.0% | 0.00% | 0.0% |
Q1 2021 | $1,127,000 | -39.2% | 37,260 | -0.5% | 0.00% | -50.0% |
Q4 2020 | $1,853,000 | -14.4% | 37,439 | -33.6% | 0.00% | -33.3% |
Q3 2020 | $2,164,000 | -13.4% | 56,381 | -2.6% | 0.00% | 0.0% |
Q2 2020 | $2,500,000 | +55.0% | 57,892 | -6.4% | 0.00% | +50.0% |
Q1 2020 | $1,613,000 | – | 61,828 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |